Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,359 stopped studies mapped to Non-Hodgkin Lymphoma and descendants · 89% state a reason
Over the 1,359 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00445068 | Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma | Phase 2 | terminated | Mar 8, 2007 | Novartis Pharmaceuticals | not stated | Not stated |
| NCT02928510 | Mechanisms of Idelalisib-Associated Diarrhea in Patients With Relapsed Chronic… | — | terminated | Oct 10, 2016 | Jonsson Comprehensive Cancer Center | withdrawn by sponsor | Other (stated, no rule matched) |
| NCT04288765 | Carfilzomib, Daratumumab, Lenalidomide and Dexamethasone as First Line Treatment in… | Phase 3 | withdrawn | Feb 28, 2020 | Grupo Cooperativo de Hemopatías Malignas | incomplete recruitment | Enrollment / accrual |
| NCT03567616 | A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants… | Phase 2 | terminated | Jun 26, 2018 | AbbVie | Following results of the primary progression-free survival analysis from Study NCT02755597,… | Sponsor / business decision |
| NCT03602898 | Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate… | Phase 2 | withdrawn | Jul 27, 2018 | Fred Hutchinson Cancer Center | Insufficient funding | Funding |
| NCT02128230 | UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete… | Phase 2 | terminated | May 1, 2014 | University of Arkansas | Low enrollment and Futility as determined by Amgen's Carfilzomib NASCR program. | Efficacy / futility |
| NCT02323230 | A Study of DPX-Survivac Vaccine Therapy in Patients With Recurrent Survivin-expressing… | Phase 2 | terminated | Dec 23, 2014 | ImmunoVaccine Technologies, Inc. (IMV Inc.) | new study | Other (stated, no rule matched) |
| NCT02757326 | ABC294640 (Opaganib) in Refractory / Relapsed Multiple Myeloma(ABC-103) | Phase 1 / Phase 2 | terminated | May 2, 2016 | RedHill Biopharma Limited | Expiration of National Cancer Institute (NCI) funding of the study. | Funding |
| NCT03687125 | Tinostamustine Conditioning and Autologous Stem Cell(TITANIUM1) | Phase 1 / Phase 2 | terminated | Sep 27, 2018 | Mundipharma-EDO GmbH | Sponsor decision based on adverse events limiting administration of higher doses required to… | Safety / toxicity |
| NCT00967343 | Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host… | Phase 2 / Phase 3 | terminated | Aug 27, 2009 | Kiadis Pharma | not stated | Not stated |
| NCT03520985 | Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma(OptiPOM) | Phase 2 | terminated | May 11, 2018 | Swiss Cancer Institute | Feasibility (low patient accrual and financial reasons) | Enrollment / accrual |
| NCT00003511 | Antineoplaston Therapy in Treating Patients With Multiple Myeloma | Phase 2 | terminated | Jan 27, 2003 | Burzynski Research Institute | Slow accrual | Enrollment / accrual |
| NCT03065790 | Early FDG PET/CT Imaging as a Measure of Response in Patients With Non-Hodgkin Lymphoma… | — | terminated | Feb 28, 2017 | Abramson Cancer Center at Penn Medicine | Adequate recruitment was not reached to continue the study. | Enrollment / accrual |
| NCT03579888 | CD19-Specific T Cells Post AlloSCT | Phase 1 | terminated | Jul 9, 2018 | M.D. Anderson Cancer Center | Study halted prematurely | Other (stated, no rule matched) |
| NCT01644253 | Phase 1b Safety and Efficacy Study of TRU-016 | Phase 1 | terminated | Jul 19, 2012 | Aptevo Therapeutics | Business decision | Sponsor / business decision |
| NCT03910439 | Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed… | Phase 2 | terminated | Apr 10, 2019 | National Cancer Institute (NCI) | Slow/Insufficient accrual/COVID-19 pandemic | COVID-19 / pandemic |
| NCT03154710 | Relevance of a Web-mediated Follow up in Patients Having a Lymphoma With a High Risk of… | N/A | terminated | May 16, 2017 | Weprom | Negative interim analysis | Efficacy / futility |
| NCT01999335 | A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory… | Phase 1 | terminated | Dec 3, 2013 | Amgen | A program evaluation identified that the safety profile and pharmacokinetic (PK) characteristics of… | Safety / toxicity |
| NCT02301494 | Effectiveness of Imiquimod Topical Cream in Early Stage Cutaneous T-cell Lymphoma(CTCL) | N/A | withdrawn | Nov 26, 2014 | Rochester General Hospital | No participants were enrolled in the study. | Enrollment / accrual |
| NCT02341209 | Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma(CTCL) | Phase 2 | terminated | Jan 19, 2015 | Rochester General Hospital | Low enrollment | Enrollment / accrual |
| NCT01125293 | Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory… | Phase 1 / Phase 2 | terminated | May 18, 2010 | Dana-Farber Cancer Institute | Per protocol, Phase II is to be terminated early if a less than 5% of the Phase II participants… | Enrollment / accrual |
| NCT01079429 | Study of DNA Copy Numbers Variations and Gene Expression Profile of Bone Marrow Plasma…(GENOMGUS) | — | terminated | Mar 3, 2010 | Rennes University Hospital | sponsor and investigator 's decision | Investigator |
| NCT02036502 | A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in… | Phase 1 | terminated | Jan 15, 2014 | Merck Sharp & Dohme LLC | Business Reasons | Sponsor / business decision |
| NCT01678443 | Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With… | Phase 1 | terminated | Sep 5, 2012 | Fred Hutchinson Cancer Center | Terminated due to low accrual. | Enrollment / accrual |
| NCT03340883 | Safety and Tolerability of BION-1301 in Adults With Relapsed or Refractory Multiple… | Phase 1 / Phase 2 | terminated | Nov 14, 2017 | Chinook Therapeutics, Inc. | No objective responses observed following completion of Phase 1 dose-escalation | Other (stated, no rule matched) |
| NCT02576275 | A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in… | Phase 3 | withdrawn | Oct 15, 2015 | SecuraBio | The scope of the program has been reduced to focus resources on studies which can potentially… | Other (stated, no rule matched) |
| NCT04342117 | Observational Trial of Real-World Treatment Utilization and Effectiveness of…(REAL) | — | terminated | Apr 10, 2020 | SecuraBio | Strategy Change | Sponsor / business decision |
| NCT03440411 | Pom-dex Versus Pom-Cyclo-dex in MM Patients With Biochemical or Clinical Relapse, During…(PO-3887) | Phase 3 | terminated | Feb 22, 2018 | Fondazione EMN Italy Onlus | Low enrollment | Enrollment / accrual |
| NCT01109407 | Natural History Study of Monoclonal Gammopathy of Undetermined Significance (MGUS) and… | — | terminated | Apr 23, 2010 | National Cancer Institute (NCI) | PI Left before primary outcome was established | Investigator |
| NCT00437034 | Aflibercept for Relapsed Multiple Myeloma | Phase 2 | terminated | Feb 19, 2007 | National Cancer Institute (NCI) | Poor accrual | Enrollment / accrual |
| NCT00003498 | Antineoplaston Therapy in Treating Patients With Non-Hodgkin's Lymphoma | Phase 2 | terminated | Jan 27, 2003 | Burzynski Research Institute | Slow accrual | Enrollment / accrual |
| NCT00176930 | Stem Cell Transplant for Hematological Malignancy | N/A | terminated | Sep 15, 2005 | Masonic Cancer Center, University of Minnesota | replaced by another study ; Trial re-written as MT2015-29 | Other (stated, no rule matched) |
| NCT03601819 | Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders | Phase 1 | terminated | Jul 26, 2018 | University of Michigan Rogel Cancer Center | Low accrual | Enrollment / accrual |
| NCT02309515 | Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic… | Phase 2 | terminated | Dec 5, 2014 | Mayo Clinic | Slow Accrual | Enrollment / accrual |
| NCT03512353 | A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple… | Phase 2 | terminated | Apr 30, 2018 | Amgen | Sponsor Decision | Sponsor / business decision |
| NCT03205046 | A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell… | Phase 1 / Phase 2 | terminated | Jul 2, 2017 | Acerta Pharma BV | Sponsor's decision not to pursue further development of the combination in DLBCL | Sponsor / business decision |
| NCT03719898 | Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma | Phase 2 | withdrawn | Oct 25, 2018 | Fox Chase Cancer Center | Slow accrual | Enrollment / accrual |
| NCT01402440 | Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large… | Phase 1 | terminated | Jul 26, 2011 | Novartis Pharmaceuticals | Study terminated due to enrolment challenges and availability of other options for DLBCL patients.… | Safety / toxicity |
| NCT01643603 | Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic… | Phase 1 | terminated | Jul 18, 2012 | Barbara Ann Karmanos Cancer Institute | Study terminated due to slow accrual. | Enrollment / accrual |
| NCT02951156 | Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator,…(Javelin DLBCL) | Phase 3 | terminated | Nov 1, 2016 | Pfizer | Study was terminated due to closure of study arms following futility analysis and difficulty in… | Efficacy / futility |
| NCT03739606 | Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer | Phase 2 | withdrawn | Nov 14, 2018 | City of Hope Medical Center | RSS recommendation | Other (stated, no rule matched) |
| NCT01121120 | Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell…(TXA127-PBSC) | Phase 2 | terminated | May 12, 2010 | Tarix Pharmaceuticals | not stated | Not stated |
| NCT01300611 | TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation(USBTXA127CBT) | Phase 1 | terminated | Feb 21, 2011 | Tarix Pharmaceuticals | not stated | Not stated |
| NCT03117361 | Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in… | Phase 2 | terminated | Apr 17, 2017 | PharmaMar | PharmaMar has decided to end this study due to the slow recruitment rate of the trial | Enrollment / accrual |
| NCT02151903 | Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in… | Phase 1 / Phase 2 | terminated | Jun 2, 2014 | Alopexx Oncology, LLC | Clinical benefit was noted before the scheduled completion of the trial and the extension study was… | Other (stated, no rule matched) |
| NCT01874288 | A Study of De-immunized DI-Leu16-IL2 Administered Subcutaneously in Participants With…(DI-Leu16-IL2) | Phase 1 / Phase 2 | terminated | Jun 11, 2013 | Alopexx Oncology, LLC | Clinical benefit was noted in the earlier portion of the trial; hence, participants were not… | Enrollment / accrual |
| NCT02483000 | Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating… | Phase 1 | terminated | Jun 26, 2015 | Fred Hutchinson Cancer Center | Closed early due to lack of funding | Funding |
| NCT01799889 | Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib… | Phase 2 | terminated | Feb 27, 2013 | Gilead Sciences | Sponsor's decision to discontinue development of entospletinib. | Sponsor / business decision |
| NCT03837457 | PRISM: Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Mycosis Fungoides Who…(PRISM) | Phase 2 | terminated | Feb 12, 2019 | miRagen Therapeutics, Inc. | Study no longer needed because eligible subjects may receive treatment with cobomarsen in a… | Other (stated, no rule matched) |
| NCT02897830 | Ixazomib, Lenalidomide, Dexamethasone Induction and Extended Consolidation Plus…(IFM2014-03) | Phase 2 | terminated | Sep 13, 2016 | University Hospital, Toulouse | negatives results | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jul 14, 2021source: clinicaltrials